1,520 Alzheimers Headlines
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute
St. Joseph's Hospital and Medical Center
"2 NEW THERAPIES FOR ALZHEIMER'S"
Produced by MD Health Channel
Executive Editor.....Anne-Merete Robbs
CEO..............Stan Swartz

Dr. Reyes and his team are constantly working on new medicines and new solutions...You will receive news alerts...information on new trials as Dr Reyes announces them!
"2 NEW THERAPIES FOR ALZHEIMER'S"
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

St. Joseph's Hospital and Medical Center



DO YOU HAVE ALZHEIMERS?
 
"HELP DR. REYES... IN HIS BATTLE TO FIND A CURE...
.HE NEEDS YOUR HELP:
YOU CAN HELP WIN THE BATTLE FOR A CURE BY JOINING A TRIAL!!"....

Stan Swartz, CEO,
The MD Health Channel



"You'll receive all medication and study based procedures at
no charge

if you qualify for one of the many trials being conducted at Barrow Neurological Institute."
 

"Dr. Reyes Changed My Life"

- John Swartz
92 Years Old
Attorney at Law
"Dr.Reyes Changed My Life "
1:18
"At 92...I had lost my will to live"
5:48
Tips on Aging
2:29
"Dr. Reyes gave me customized health care"
2:09

Patricio Reyes M.D.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute

St. Joseph's Hospital and Medical Center
"PRESERVING BRAIN FUNCTIONS "
Runtime: 50:22
Runtime: 50:22
"2 NEW THERAPIES FOR ALZHEIMER'S"
Runtime: 10:27
Runtime: 10:27
ALZHEIMER'S AWARENESS PROGRAMS
Runtime: 5:00
Runtime: 5:00
BIOMEDICAL RESEARCH IN ALZHEIMER'S DISEASE
PDF Document 850 kb

Download Free

4 TALES OF NEUROSURGERY &
A PIANO CONCERT BY DR. SPETZLER...
Plus 2 books written by Survivors for Survivors!
Robert F. Spetzler M.D.
Director, Barrow Neurological Institute

J.N. Harber Chairman of Neurological Surgery

Professor Section of Neurosurgery
University of Arizona
TALES OF NEUROSURGERY:
A pregnant mother..a baby..faith of a husband.. .plus... Cardiac Standstill: cooling the patient to 15 degrees Centigrade!
Lou Grubb Anurism
The young Heros - kids who are confronted with significant medical problems!
2 Patients...confronted with enormous decisions before their surgery...wrote these books to help others!
A 1 MINUTE PIANO CONCERT BY DR. SPETZLER

Michele M. Grigaitis MS, NP
Alzheimer's Disease and Cognitive Disorders Clinic

Barrow Neurological Clinics
COPING WITH DEMENTIA
 
Free Windows Media Player Click

Links
Barrow Neurological Institute

Archives
October 2006  
November 2006  
December 2006  
January 2007  
February 2007  
March 2007  
May 2007  
June 2007  
November 2007  
December 2007  
April 2008  
July 2008  
August 2008  
September 2008  
October 2008  
November 2008  
December 2008  
January 2009  
February 2009  
March 2009  
April 2009  
May 2009  
February 2010  
March 2013  
May 2013  
November 2013  
January 2014  
February 2014  
March 2014  
April 2014  
May 2014  
June 2014  
July 2014  
June 2016  
July 2016  
August 2016  
September 2016  
October 2016  
November 2016  
December 2016  
January 2017  
February 2017  
March 2017  
April 2017  
May 2017  
June 2017  
July 2017  
August 2017  
September 2017  
October 2017  
November 2017  
December 2017  
January 2018  
February 2018  

This page is powered by Blogger. Isn't yours?

Monday, September 5, 2016

 

Pilot Study of MEND Protocol for Alzheimer’s Shows Results in Those with Mild Decline























At the recent Alzheimer’s Association International Conference (AAIC) 2016, held in Toronto, Canada, Muses Labs presented data from a pilot study of its MEND Protocol for treatment of early Alzheimer’s disease.

The few drugs available today to slow the progression of Alzheimer’s disease target individual brain factors. Plenty of research, however, shows that dementia is linked to an array of risk factors, suggesting that some form of a combination therapy is likely to be more effective.

But the factors involved also vary among individuals, and a one-combination-therapy-that-fits-all approach is unsuitable.  Muses Labs reports that it has found a way to address these issues simultaneously in each individual patient.

MEND Protocol is a multi-step cognitive evaluation process, that uses advanced data processing technology to first assess which risk factors are present in an individual. According to the company, more than 50 drivers of cognitive decline exist, of which the top 12 are low thyroid hormone levels, high homocysteine levels, bad diet, insulin resistance, ApoE4, imbalance in metals, stress, depression, elevated blood fats, low exercise, poor sleep, and inflammation.

An initial examination, therefore, includes a genetic analysis, medical history, and a lifestyle analysis in addition to laboratory test and cognitive screenings.

Taking these and additional risk factors into account, the Muses software then uses advanced algorithms to propose a treatment plan that can easily be adapted by a physician.

“Unlike drugs that address a single issue, our evidence-based combination approach targets the 50-plus known causes of cognitive decline that often exist simultaneously,” Vik Chandra, Muses Labs CEO, told Alzheimer’s News Today. “In addition to FDA-approved medications, our solution also includes supplements and lifestyle changes personalized for a patient’s specific needs.

“It is important to note that patients can benefit from our methodology today. The methodology does not depend upon unapproved medications,” he added.

According to Muses, the MEND protocol invariably needs more than just a consultation with a physician. Given the complex nature of the intervention, which includes lifestyle changes, coaching is an integral part of the treatment. Once a patient’s data is processed and a treatment plan is set, a patient receives coaching once a week with follow-up in three-month cycles.

The coaching is intended to overcome the inertia to introduce lifestyle changes, and a coach starts by prioritizing goals that quickly produce measurable results to increase encouragement.

The pilot study, conducted in 19 patients, showed that in people at risk for Alzheimer’s but with no obvious decline, as well as in those with mild cognitive impairment, two or more cycles of the three-month intervention improved memory function and biomarkers of cognitive decline. But the intervention did not manage to lower levels of blood stress hormones.

For those in early stages of Alzheimer’s disease, the pilot study did not find evidence of improved cognition. But the study was small, and Muses plans to bring the protocol to randomized clinical trials for more rigid testing.

People who joined the study tended to be well-educated, and a large proportion of them had the ApoE4 gene — the most well-known genetic Alzheimer’s risk factor. The sample is, therefore, not representative of the general population, again showing the need for a randomized trial.

“As a society, we should develop combination approaches in addition to continuing the work on silver-bullet drugs. We should not leave any stone unturned,” said Chandra.

Besides testing the MEND protocol in larger, long-term studies, Muses Labs is now exploring partnerships to bring a direct-to-consumer offering focused on optimizing cognitive function to the market.

Story Source: The above story is based on materials provided by ALZHEIMERSNEWSTODAY
Note: Materials may be edited for content and length

Labels: